These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 24793817)
21. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Krop I; Winer EP Clin Cancer Res; 2014 Jan; 20(1):15-20. PubMed ID: 24135146 [TBL] [Abstract][Full Text] [Related]
22. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126 [TBL] [Abstract][Full Text] [Related]
23. HER2-positive metastatic breast cancer: a changing scenario. Mustacchi G; Biganzoli L; Pronzato P; Montemurro F; Dambrosio M; Minelli M; Molteni L; Scaltriti L Crit Rev Oncol Hematol; 2015 Jul; 95(1):78-87. PubMed ID: 25748080 [TBL] [Abstract][Full Text] [Related]
24. [Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers]. Guerin M; Sabatier R; Gonçalves A Bull Cancer; 2015 Apr; 102(4):390-7. PubMed ID: 25790739 [TBL] [Abstract][Full Text] [Related]
25. Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. Isakoff SJ; Baselga J J Clin Oncol; 2011 Feb; 29(4):351-4. PubMed ID: 21172881 [No Abstract] [Full Text] [Related]
26. HER2 testing in patients with breast cancer. Dixon JM; Wilson V; Verrill M; Symmans WF BMJ; 2012 Jun; 344():e3958. PubMed ID: 22689887 [No Abstract] [Full Text] [Related]
27. Breast cancer brain metastases responding to primary systemic therapy with T-DM1. Bartsch R; Berghoff AS; Preusser M J Neurooncol; 2014 Jan; 116(1):205-6. PubMed ID: 24065570 [No Abstract] [Full Text] [Related]
28. Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. Van den Mooter T; Teuwen LA; Rutten A; Dirix L Expert Opin Biol Ther; 2015 May; 15(5):749-60. PubMed ID: 25865453 [TBL] [Abstract][Full Text] [Related]
29. Emerging strategies for the dual inhibition of HER2-positive breast cancer. Konecny GE Curr Opin Obstet Gynecol; 2013 Feb; 25(1):55-65. PubMed ID: 23241641 [TBL] [Abstract][Full Text] [Related]
31. HER2-directed therapy: current treatment options for HER2-positive breast cancer. Ahmed S; Sami A; Xiang J Breast Cancer; 2015 Mar; 22(2):101-16. PubMed ID: 25634227 [TBL] [Abstract][Full Text] [Related]
32. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study. Yardley DA; Krop IE; LoRusso PM; Mayer M; Barnett B; Yoo B; Perez EA Cancer J; 2015; 21(5):357-64. PubMed ID: 26389758 [TBL] [Abstract][Full Text] [Related]
33. NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer. Elsada A; Doss S; Robertson J; Adam EJ Lancet Oncol; 2016 Feb; 17(2):143-144. PubMed ID: 26703893 [No Abstract] [Full Text] [Related]
34. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681 [TBL] [Abstract][Full Text] [Related]
35. Trastuzumab emtansine: determining its role in management of HER2+ breast cancer. Doroshow DB; LoRusso PM Future Oncol; 2018 Mar; 14(7):589-602. PubMed ID: 29214842 [TBL] [Abstract][Full Text] [Related]
36. Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer. Weiler D; Diebold J; Strobel K; Aebi S; Gautschi O J Thorac Oncol; 2015 Apr; 10(4):e16-7. PubMed ID: 25789838 [No Abstract] [Full Text] [Related]
37. From linear 'dogma' and trastuzumab-emtansine to future transcriptional circuitry-based drug discovery for breast cancer. Lianos GD; Roukos DH Future Oncol; 2014 Feb; 10(2):145-8. PubMed ID: 24490597 [No Abstract] [Full Text] [Related]
38. Checkpoint Inhibitors Boost Power of Antibody-Drug Conjugate. Cancer Discov; 2016 Feb; 6(2):OF3. PubMed ID: 26701087 [TBL] [Abstract][Full Text] [Related]
39. [Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer]. Ismaili N; Belbaraka R; Elomrani A; Khouchani M; Tahri A Presse Med; 2013 Nov; 42(11):1461-8. PubMed ID: 23721860 [TBL] [Abstract][Full Text] [Related]